NEW YORK (360Dx) – Cancer detection firm Oncimmune today announced the first distribution deals for its autoantibody-based lung cancer test.

Under the terms of the deals, Israel-based Best Medical Opinion and South Korea-based Dow Biomedica/Biodiscovery will distribute Oncimmune's EarlyCDTLung cancer test in those countries. The agreements allow for the sale of the test as a central laboratory test while Oncimmune finishes the CE marking of a kit form of EarlyCDTLung.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.